Physician profile
A Ridgeway
NPI 1326013558
$5,364.83
in general payments reported to CMS, 2019-2025
31 companies · $913 in 2025
The $913 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $807 · 2021: $905 · 2022: $537 · 2023: $462 · 2024: $956 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.99 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,485.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,247.08 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Indivior INC. | $452.42 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $286.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.99 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $197.76 | 2019-2025 | |
| Insmed, INC. | $166.30 | 2020-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $158.22 | 2021-2025 | Zerbaxa, Dificid |
| Inspire Medical Systems, INC. | $142.47 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $137.48 | 2024-2025 | Dupixent |
| Genzyme Corporation | $113.22 | 2024-2025 | |
| Mylan Specialty L.P. | $109.41 | 2019-2023 | Yupelri |
| Novo Nordisk INC | $83.22 | 2023-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $63.21 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $61.50 | 2021-2023 | |
| Pfizer INC. | $57.05 | 2020 | |
| Orexo US, INC. | $42.08 | 2019-2021 | |
| Grifols USA, LLC | $35.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $34.59 | 2019 | |
| Axsome Therapeutics, INC. | $30.20 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $22.50 | 2021 | |
| 3b Medical, INC. | $20.16 | 2025 | Luna |
| Amgen INC. | $19.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.48 | 2022 | |
| Gilead Sciences, INC. | $14.06 | 2021 | |
| Allergan, INC. | $13.95 | 2020 | |
| Irhythm Technologies, INC. | $13.89 | 2022 | |
| Eisai INC. | $12.49 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw A Ridgeway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.